Results 31 to 40 of about 46,312 (227)
Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service [PDF]
, 2018 Background: Major orthopedic surgery, such as elective total hip replacement (eTHR) and elective total knee replacement (eTKR), are associated with a higher risk of venous thromboembolism (VTE) than other surgical procedures.
Anderson +53 more
core +4 more sources
Managing atrial fibrillation in the global community: The European perspective. [PDF]
, 2013 Atrial fibrillation is a common, global problem, with great personal, economic and social burdens. As populations age it increases in prevalence and becomes another condition that requires careful chronic management to ensure its effects are minimised ...
Camm, AJ +3 more
core +1 more source
HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
Рациональная фармакотерапия в кардиологии, 2015 Dabigatran is the new oral anticoagulant that directly inhibits thrombin (factor IIa). In RE-LY clinical trial dabigatran 150 mg b.i.d was more effective than warfarin in prevention of ischemic stroke and systemic embolic events in more than 18000 ...
S. V. Moiseev
doaj +3 more sources
Thrombocytopenia induced by dabigatran: two case reports
BMC Neurology, 2017 Background Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. heparin) are widely used to prevent thromboembolic disorders (e.g. myocardial infarction, venous thromboembolism, and stroke).
Hyun Goo Kang +3 more
doaj +1 more source
Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]
, 2014 Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm +72 more
core +1 more source
The year in cardiology: arrhythmias and pacing. [PDF]
, 2020 During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the management of patients with supraventricular ...
Calkins, H +4 more
core +4 more sources
Case Reports in Critical Care, 2016 Purpose. To report the ability to remove serum dabigatran using continuous renal replacement therapy (CRRT) in a patient with life-threatening bleeding. Summary.
Sara E. Parli +2 more
doaj +1 more source
New indications for dabigatran: A suggestion from a drug use evaluation study
Journal of Research in Pharmacy Practice, 2017 Objective: Dabigatran etexilate is a novel oral anticoagulant with several advantages over warfarin such as no need for routine monitoring and fewer drug interactions. This drug was added to our hospital's formulary in 2012.
Farzaneh Ashrafi +2 more
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2020 Routine coagulation tests do not enable rapid, accurate determination of direct oral anticoagulant (DOAC) therapy. The ecarin clotting assay (ECA), performed on the ClotPro viscoelastic testing device, may enable sensitive and specific detection of ...
Alan Yean Yip Fong MRCP +6 more
doaj +1 more source
, 2015 The bottom line Clarify the warfarin dose that the patient is taking, and check for co-existing problems (such as liver disease or cancer), dietary changes, and intake of alcohol and other drugs that may increase risk of bleeding or affect ...
Chevassut, Timothy J +2 more
core +1 more source